Purpose: To review the clinical and pathological characteristics of patients with posttransplant lymphoproliferative disorders (PTLD) occurring after solid organ transplantation and determine the influence of these characteristics on response to treatment and survival.
Introduction
Recipients of solid organ transplants are at a 25-to 500-fold increased risk for developing posttransplant lymphoproliferative disorders (PTLD) in the first year after transplant [1] . Posttransplant lymphoproliferative disorders are a clinically and morphologically heterogeneous group of diseases [2, 3] .
The treatment of PTLD is highly individualized due to these variances in clinical and pathological presentations as well as the unpredictable response between patients using similar treatments [4, 5] . These differences constitute an obstacle in developing a strict algorithm for the management of PTLD. With few exceptions, attempts to identify features that predict response to therapy have met with limited success.
The purpose of this study is to review the clinical and pathologic characteristics of patients diagnosed with PTLD and identify those features which might assist in formulating treatment decisions and in determining prognosis.
defined as the time from diagnosis of PTLD to death or most recent follow-up Patients were classified, according to their clinical presentation, into either an infectious mononucleosis-like syndrome or mass presentation (previously described [4] ) and a third 'organ graft failure' group (patients with laboratory evidence of dysfunction of the transplanted organ without other complaints).
Biopsy material was reviewed by experienced hematopathologists (T. Greiner, B. Smir). Histology specimens were stained with hematoxylin and eosin. Cell type was determined through immunohistochemistry. Clonahty was ascertained by immunohistochemistry. immunoglobulin gene rearrangement or cytogenetic translocation using polymerase chain reaction or Southern blot analysis. The presence of Epstein-Barr virus was established in all samples via detection of latent membrane protein using immunohistochemistry, polymerase chain reaction or Southern blot analysis.
No formal treatment algorithm was established. Most patients had an initial trial of cessation or a decrease of ^ 50% of immunosuppression. Additional treatments included intravenous acyclovir or ganciclovir, immunoglobulins (IVIG), interferon alpha, surgery, cytotoxic chemotherapy or radiation therapy. Unless obvious progression occurred, patients were observed for 7-14 days on each new therapy before a more aggressive treatment was recommended.
The overall survival was calculated according to the method of Kaplan and Meier. The log-rank test was used to determine the influence of clinical presentation, clonality and time from transplant to a diagnosis of PTLD on overall survival [6] .
Patients and methods
Thirty-two solid organ recipients transplanted between December 1976 and April 1995 were diagnosed or referred to our institution with a diagnosis of PTLD between June 1988 and September 1995. Patient data was obtained through chart review
The time to diagnosis is defined as the time from a patient's first transplant to the date of PTLD diagnosis. The length of survival is (Table 1) Twenty-two patients were male. The median age at diagnosis was 32 years and a majority of patients were or IV. Fifteen (48%) patients had previously experienced one or more episodes of graft rejection requiring increased immunosuppression. The characteristics of the clinical presentation groups are summarized in Table 2 .
Results

Clinical characteristics
Pathologic characteristics (Table 3) Forty percent of tumors had a histologically monomorphous appearance. The majority of tumors were of B-cell lineage (n = 28, 87.5%). Two patients had T-cell tumors and two patients had a mixed B-and T-cell population. Sixteen of twenty-one tumors assessed for clonality were monoclonal.
Treatment
Thirty patients were initially treated with a reduction or cessation of immunosuppression. One patient was diagnosed at autopsy and another died before treatment could be instituted.
Twenty-one patients received acyclovir or ganciclovir alone (n = 4) or in combination with other treatment modalities (n = 17). Seven out of eight patients that underwent surgery required no other treatment modality beyond a reduction in immunosuppression. Twelve patients received cytotoxic chemotherapy. Three of those patients also received radiation therapy. The most commonly used chemotherapy regimen was CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone).
Patients with infectious mononucleosis-like presentations failed to respond to any medical therapy. In contrast, nearly 70% of patients presenting with graft failure responded to noncytotoxic chemotherapy. Patients with mass presentation responded to noncytotoxic chemotherapy in 40%-50% of cases and close to half of the nonresponders benefited from subsequent cytotoxic therapy (data not shown).
Survival
Eighteen patients are alive and disease free with a median follow-up of sixty-three months. PTLD was felt to be the direct cause of death in five patients. Other causes of death included sepsis (n = 3), multiorgan system failure (n -1), cerebrovascular hemorrhage (n = 1), intraoperative hemorrhage (n -1) and renal failure (n = 1). Two patients died at home of unknown cause but were free of disease at last contact.
Overall five-year survival is estimated at 59% (95% confidence interval: 40%, 77%) (Figure 1 ). Graft function was maintained in 16 survivors. Five year survival estimates were 38%, 60% and 78% for patients with infectious mononucleosis-like syndrome, mass or graft failure presentations respectively (P = 0.076). Five-year survival tended to be worse among patients with monoclonal PTLD (47% vs. 100%, P = 0.07) and among those diagnosed within the first year posttransplant (44% vs. 83%, P = 0.14).
Discussion
PTLD is usually a B-cell lymphoproliferation induced by EBV infection [7] . Risk factors for developing PTLD include EBV seronegativity, cytomegalovirus donor/ recipient mismatch, rejection requiring 0KT3 without prior antilymphocyte antibody therapy, type of organ transplanted and, in allogeneic bone marrow transplantation, the use of T-cell depleted donor graft [8, 9] .
Reports detailing the resolution of PTLD after decreasing immunosuppression emphasize the role of the immune surveillance system in controlling this disease [10] . However, not all patients respond to this intervention alone. Various analyses have attempted to identify characteristics that predict prognosis and response to treatment. Characteristics reported to be associated with a poor response to decreased immunosuppression include bcl-6 mutations, lactate dehydrogenase >1100 U/l, bacterial and/or fungal infection, organ failure and multiorgan involvement [11, 12] . In a review of 20 cases by Armitage et al., patients developing PTLD within 12 months of transplantation had a lower mortality, less disseminated disease and better response to decreased immunosuppression [13] . Morrison et al. found that among 26 patients the only characteristic associated with response to treatment was a younger age. Other characteristics, including sex, immunosuppressive regimen, time from transplant to diagnosis, lactate dehydrogenase and extent of disease, were not associated with response to therapy [14] . Thus, the data regarding prognostic and predictive features is conflicting.
In this series of patients, several characteristics demonstrated a trend towards worse survival: diagnosis within the first year after transplant, monoclonal tumor and infectious mononucelosis-like presentation. In contrast to the results of Armitage et al., we found that nearly half (45%) of patients diagnosed within the first year posttransplant had more advanced disease and a greater predominance of extranodal disease. Caution is required when interpreting clonality data given the limitations of sampling and molecular techniques. Our analysis suggests that clinical presentation may assist in guiding therapy, although this observation clearly requires further verification.
This report suffers the limitations of any retrospective study. Despite a comparatively large number of cases, it lacks sufficient strength to achieve statistical significance and undertake multivariate analysis. The lack of a formal treatment algorithm impairs the ability to reach conclusions regarding response to therapy. Beyond deficiencies of study type, there are drawbacks which are inherent to the disease itself, such as the heterogeneity of tumor types, differences in organs transplanted and predominance of clinical presentations according to age groups. Furthermore, only the patients with more advanced disease or who failed early interventions may have been referred, creating a selection bias.
Nevertheless, some observations can be made. First, this analysis confirms previous observations that surgery has a definite role in selected patients. Second, PTLD may present as organ graft failure and should be considered within the differential diagnosis of said presentation. Third, these data suggest that clinical features may be helpful in stratifying patients as a guide for therapy. Lastly, patients with PTLD can tolerate intensive chemotherapy and achieve long-term survival.
